The Journal of Neuroscience

Ibogaine By David Dardashti Shares Insight On New Study By Stanford University

Retrieved on: 
Thursday, February 1, 2024

The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.

Key Points: 
  • The study, which involved soldiers who had experienced both physical and psychological trauma, offers insight towards the potential therapeutic benefits of ibogaine.
  • The University of California has asserted that ibogaine has the ability to increase serotonin levels, which may contribute to the recovery of damaged brain cells.
  • Medicalnewstoday, a leading source of medical news and information, has also reported on the potential of ibogaine in promoting cell recovery.
  • Ibogaine By David Dardashti is proud to be at the forefront of this research and looks forward to further advancements in the field.

NTT Study: Artificial Neural Networks for Recognizing Natural Sounds Exhibit Human-Like Responses

Retrieved on: 
Tuesday, August 1, 2023

Nippon Telegraph and Telephone Corporation (headquartered in Chiyoda-ku, Tokyo; Akira Shimada, President & CEO; hereinafter "NTT") has discovered that artificial neural networks (NNs, *1) that recognize natural sounds (*2) show human-like responses to changes in sound amplitude.

Key Points: 
  • Nippon Telegraph and Telephone Corporation (headquartered in Chiyoda-ku, Tokyo; Akira Shimada, President & CEO; hereinafter "NTT") has discovered that artificial neural networks (NNs, *1) that recognize natural sounds (*2) show human-like responses to changes in sound amplitude.
  • NTT Laboratories has been conducting studies using artificial neural networks (NN, *1) to understand auditory AM processing.
  • AM sounds were fed to NNs trained to recognize natural sounds (*4) and their responses were examined.
  • The results suggest that the response to AM sound in animal brains might be a result of adaptation to recognize natural sounds.

Talking to babies may contribute to brain development – here's how to do it

Retrieved on: 
Tuesday, May 16, 2023

Talking to your baby or toddler shapes the structure of their brain, my colleagues and I have discovered.

Key Points: 
  • Talking to your baby or toddler shapes the structure of their brain, my colleagues and I have discovered.
  • The children wore a small audio recorder in a specially made vest for between one and three days.
  • We recorded all the language input they received – such as adults talking to the child, adults talking to each other and siblings talking.

Brain development

    • We were particularly interested in the amount of myelin in brain areas associated with language processing.
    • The question was whether children who heard more language would have more myelin in language-processing brain regions.
    • During the first year of life, the brain is busy growing new cells, so hearing lots of language may ramp up brain growth.
    • This suggests that talking matters just as much at six months as at 30 months, but it affects the brain differently because the brain is in a different “state”.

Good ways to talk to babies and toddlers

    • Of course, there are different ways babies and toddlers can be exposed to talk – reading to them, singing to them and talking to other adults when they are around.
    • Parents might wonder if some ways of talking to babies are better than others.
    • Research has found that children raised in language-rich environments may have a leg up in early language development.
    • This advantage, however, came from talk directed at the child – not speech between others overheard by the child.

EpiVario Appoints New Scientific Advisory Board Members and Expands Operations

Retrieved on: 
Tuesday, October 11, 2022

PHILADELPHIA, Oct. 11, 2022 /PRNewswire/ -- EpiVario, a biotech company developing novel therapeutics for memory-related psychiatric disorders, today announced that Anthony Ford-Hutchinson, PhD, and Paul Kenny, PhD, have been appointed to the Company's Scientific Advisory Board (SAB). They each bring deep industry and scientific experience that will help further guide EpiVario on the translation of its core discoveries through research into development, and future commercialization.

Key Points: 
  • "We are thrilled to welcome Dr. Ford-Hutchinson and Dr. Kenny to our Scientific Advisory Board," said Thomas Kim, President and CEO of EpiVario.
  • Currently, he serves as a board member or scientific advisor to various startup companies, corporations, and private foundations.
  • "I am excited to join EpiVario's Scientific Advisory Board, to help drive translation and development of its exciting pipeline that may offer new therapeutic options to patients in need."
  • Along with the new appointments to its SAB, EpiVario is expanding its operations having secured additional funding from angel investors.

Closer Study of Major Autism Gene Suggests Possible Treatment Approach

Retrieved on: 
Friday, September 23, 2022

CINCINNATI, Sept. 23, 2022 /PRNewswire/ -- Research led by a scientist at Cincinnati Children's who primarily studies brain tumors may open doors for improved treatment of autism.

Key Points: 
  • Autism spectrum disorder (ASD) affects about one in 40 children between ages 3 and 17, according to the National Survey of Children's Health.
  • Of those tested for various genes linked to the condition, nearly everyonewith disruptive mutations of the gene CHD8 has autism.
  • "Longer term, it also would require large scale clinical trials before a treatment could be approved for human use."
  • The restoration was not complete but was powerful enough that the drug merits closer study as a potential way to augment neurogenesis in CHD8-deficiency, Lu says.

No Evidence of Data Manipulation in Science Publication on Simufilam

Retrieved on: 
Thursday, August 18, 2022

At some point it becomes irrational for our detractors to repeat over and over again the same old tired mantra of data manipulation.

Key Points: 
  • At some point it becomes irrational for our detractors to repeat over and over again the same old tired mantra of data manipulation.
  • In May 2022, Neurobiology of Aging investigated and found no evidence of data manipulation in a paper on simufilam published in that journal in 2017.
  • The Editor-in-Chief stated: After careful examination of these original material, Neuroscience found no evidence of manipulation of the western blot data or other figures of this publication.
  • The Editor-in-Chief previously authorized Cassava Sciences to share a statement on this matter, including: No evidence of data manipulation was found for Western blot data.

Boost in Nerve-Growth Protein Helps Explain Why Running Supports Brain Health

Retrieved on: 
Monday, May 16, 2022

Experts have long understood that regular running raises dopamine activity in the brain and may protect nerve cells from damage.

Key Points: 
  • Experts have long understood that regular running raises dopamine activity in the brain and may protect nerve cells from damage.
  • In addition, past research has tied exercise-driven boosts in the dopamine-triggering chemical called brain-derived neurotrophic factor (BDNF) and in dopamine levels to improvements in learning and memory.
  • Additionally, when BDNF levels were artificially reduced, running did not lead to additional dopamine release.
  • Further funding support was provided by the Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders.

Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates

Retrieved on: 
Monday, February 28, 2022

AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the year ended December 31, 2021 and provided clinical and business updates.
  • Cassava Sciences Phase 3 studies are now recruiting patients with mild to moderate Alzheimers disease.
  • At December 31, 2021, cash and cash equivalents were $233.4 million, compared to $93.5 million at December 31, 2020, with no debt.
  • Net cash used in operations full-year 2021 was $30.2 million, net of reimbursements received from the National Institutes of Health (NIH) grant awards.

Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease

Retrieved on: 
Thursday, December 23, 2021

Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimers disease.

Key Points: 
  • Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimers disease.
  • I think clinical sites around the country are quite excited by the potential of oral simufilam to impact Alzheimers disease, said James Kupiec, MD, Chief Clinical Development Officer at Cassava Sciences.
  • Rethink-ALZ.com is dedicated to enhance patient experience and enrollment for both of our on-going Phase 3 studies of oral simufilam in Alzheimers disease.
  • Over 25 clinical sites across the country are now participating in the Phase 3 efficacy studies of simufilam in Alzheimers disease.

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

Retrieved on: 
Tuesday, December 21, 2021

Editor-in-Chief States: After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.

Key Points: 
  • Editor-in-Chief States: After Careful Examination of These Original Material, Neuroscience [Journal] Found No Evidence of Manipulation of the Western Blot Data or Other Figures of This Publication.
  • AUSTIN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc., (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators.
  • After careful examination of these original material, Neuroscience found no evidence of manipulation of the Western blot data or other figures of this publication.
  • In November 2021, Cassava Sciences reported that a different science journal (i.e., Journal of Neuroscience) also found no evidence to support allegations of data manipulation in an article it published in 2012.